Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
MultiPlan (MPLN) received a notice from the NYSE stating non-compliance with the minimum price criteria, giving the company six months to regain compliance. The company plans to notify the NYSE of its intent to cure the deficiency, which may involve a reverse stock split. Despite the notice, the Common Stock will continue to be listed and traded on the NYSE. The company reassures shareholders that the notice has no immediate impact on its business operations or reporting obligations.
The notification received by MultiPlan Corporation from the NYSE regarding non-compliance with the minimum price criteria is a significant event that warrants attention from investors. The stipulation that the company’s stock must maintain an average closing price of at least $1.00 over a consecutive 30 trading-day period is a standard requirement for continued listing. Falling below this threshold is often seen as a red flag, indicating potential underlying financial or operational weaknesses.
From a financial perspective, the company’s consideration of a reverse stock split to cure the deficiency suggests a proactive approach to maintaining its listing status. However, such a move can have mixed implications. On one hand, it could improve the perceived market value of the stock by increasing the price per share, potentially attracting institutional investors who may avoid stocks under a certain price. On the other hand, it could also be viewed as a cosmetic change that does not address the fundamental reasons for the stock’s decline. Investors should closely monitor the company’s performance metrics and management’s execution of its Growth Plan to assess the likelihood of sustainable improvement in stock value.
Market perception following a notice of non-compliance can vary. In some cases, it may lead to increased volatility as traders react to the perceived risk of delisting. For MultiPlan Corporation, the emphasis on continuing to trade on the NYSE and the assurance that business operations and reporting obligations remain unaffected is critical. It’s important to note that the company’s strategic focus on its Growth Plan and commitment to shareholder value could mitigate some of the negative sentiment surrounding the notice.
Investors should consider the broader industry context when evaluating MultiPlan’s situation. If the company operates in a sector experiencing overall challenges, the stock price issue might be symptomatic of sector-wide trends rather than company-specific problems. Conversely, if the sector is thriving, the company’s inability to maintain the minimum stock price might be more concerning. Additionally, investor sentiment and confidence can be influenced by the company’s transparency and communication regarding the steps it will take to regain compliance.
– Company has six months to regain compliance with the minimum price criteria for continued listing on the NYSE
– Company remains focused on executing its Growth Plan and on delivering results and shareholder value
NEW YORK–(BUSINESS WIRE)– MultiPlan Corporation (NYSE: MPLN) (“MultiPlan” or the “Company”) announced today that it received notice (the “Notice”) on March 28, 2024 from the New York Stock Exchange (the “NYSE”) that, as of March 27, 2024, it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”) because the average closing price of the Company’s Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period.
Pursuant to Section 802.01C, the Company has a period of six months following the receipt of the Notice to regain compliance with the minimum price criteria. In accordance with Section 802.01C, the Company plans to notify the NYSE within 10 business days of its receipt of the Notice of its intent to cure the deficiency, which may include, if necessary, effecting a reverse stock split, subject to approval by the Board of Directors and stockholders of the Company.
The Company may regain compliance with the minimum price criteria at any time during the six-month cure period if, on the last trading day of any calendar month during the cure period, the Company has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month.
The Notice has no immediate impact on the listing of the Common Stock, which will continue to be listed and traded on the NYSE during this period, subject to the Company’s compliance with the other continued listing requirements of the NYSE.
The Notice does not affect the Company’s business operations or its reporting obligations with the Securities and Exchange Commission, nor does it conflict with or prompt default under any of the Company’s material debt or other agreements. The Company fully intends to regain compliance and will take necessary action to ensure that the Common Stock continues to be listed on the NYSE. The Company remains focused on executing its Growth Plan and on delivering results and shareholder value.
About MultiPlan
MultiPlan is committed to delivering affordability, efficiency, and fairness to the US healthcare system by helping healthcare payors manage the cost of care, improve their competitiveness, and inspire positive change. Leveraging sophisticated technology, data analytics, and a team rich with industry experience, MultiPlan interprets customers’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based, analytics-based, and data and decision science services. MultiPlan is a trusted partner to over 700 healthcare payors, brokers, employers and groups, and supplemental carriers in the commercial health, government, and property and casualty markets. For more information, visit multiplan.com.
Forward Looking Statements
This press release contains forward-looking statements. These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “seeks,” “projects,” “forecasts,” “intends,” “plans,” “may,” “will” or “should” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. The forward-looking statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and speak only as of the date they are made. Any forward-looking statements that we make herein are not guarantees of future performance and actual results may differ materially from those in such forward- looking statements as a result of various factors. Factors that may impact such forward-looking statements also include the factors discussed under “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023; and other factors beyond our control. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company’s periodic and other filings are accessible on the SEC’s website at www.sec.gov. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240329587713/en/
Investor Relations
Luke Montgomery, CFA
SVP, Finance & Investor Relations MultiPlan
866-909-7427
Shawna Gasik
AVP, Investor Relations MultiPlan
866-909-7427
Media Relations
Kahler Buckley
Matter Communications for MultiPlan 860-604-1073
Source: MultiPlan Corporation
MultiPlan (MPLN) received a notice from the New York Stock Exchange (NYSE) stating non-compliance with the continued listing standard due to the average closing price of its Common Stock being less than $1.00 per share over a 30 trading-day period.
MultiPlan (MPLN) has a period of six months following the receipt of the notice to regain compliance with the minimum price criteria.
MultiPlan (MPLN) plans to notify the NYSE within 10 business days of its intent to cure the deficiency, which may include effecting a reverse stock split, subject to approval by the Board of Directors and stockholders.
Yes, despite the notice, the Common Stock of MultiPlan (MPLN) will continue to be listed and traded on the NYSE during the six-month cure period, as long as the company complies with the other continued listing requirements of the NYSE.
The notice from the NYSE does not have an immediate impact on MultiPlan ‘s (MPLN) business operations or reporting obligations with the Securities and Exchange Commission. It also does not conflict with or prompt default under any of the company’s material debt or other agreements.
